{"id":56985,"date":"2026-03-21T03:15:07","date_gmt":"2026-03-21T03:15:07","guid":{"rendered":"https:\/\/www.europesays.com\/at\/56985\/"},"modified":"2026-03-21T03:15:07","modified_gmt":"2026-03-21T03:15:07","slug":"marinomed-will-mit-kapitalerhoehung-finanzluecke-schliessen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/at\/56985\/","title":{"rendered":"Marinomed will mit Kapitalerh\u00f6hung Finanzl\u00fccke schlie\u00dfen"},"content":{"rendered":"<p>Aufgrund der &#8222;bisher nicht in ausreichender H\u00f6he von der Gesellschaft vereinnahmten Zahlungen aus der \u00dcbertragung des Carragelose Gesch\u00e4fts an Unither Pharmaceuticals&#8220;, habe die Gesellschaft kurzfristigen Kapitalbedarf, um ihren absehbaren Liquidit\u00e4tsbedarfs von rund 2 Mio. Euro bis zur Mitte des Gesch\u00e4ftsjahres 2026 zu decken, teilte Marinomed weiter mit. Der Nettoemissionserl\u00f6s der Kapitalerh\u00f6hung solle daher &#8222;f\u00fcr die Erf\u00fcllung des Sanierungsplans und die Schlie\u00dfung der Finanzierungsl\u00fccke verwendet werden&#8220;.<\/p>\n","protected":false},"excerpt":{"rendered":"Aufgrund der &#8222;bisher nicht in ausreichender H\u00f6he von der Gesellschaft vereinnahmten Zahlungen aus der \u00dcbertragung des Carragelose Gesch\u00e4fts&hellip;\n","protected":false},"author":2,"featured_media":56986,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[46,42,20072,23189,23191,95,9342,90,89,22885,22928,22883,13492,91,94,44,23190,93,92,22933,22936,22937,22884],"class_list":{"0":"post-56985","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-unternehmen-maerkte","8":"tag-at","9":"tag-austria","10":"tag-biotechnologie","11":"tag-biotechnologie-news","12":"tag-branchen-news","13":"tag-business","14":"tag-chemische-industrie","15":"tag-companies","16":"tag-companies-markets","17":"tag-corporates-news","18":"tag-europa-news","19":"tag-kurz-news","20":"tag-marinomed","21":"tag-markets","22":"tag-maerkte","23":"tag-oesterreich","24":"tag-pharma-news","25":"tag-unternehmen","26":"tag-unternehmen-maerkte","27":"tag-wien-autorevue","28":"tag-wirtschaft-osterreich-trend","29":"tag-wirtschaft-und-finanzen-news","30":"tag-wissenupdate-me-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@at\/116264994270437909","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/posts\/56985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/comments?post=56985"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/posts\/56985\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/media\/56986"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/media?parent=56985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/categories?post=56985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/at\/wp-json\/wp\/v2\/tags?post=56985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}